metsera ipo - Search News

IPO, Metsera

Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable appetite for such treatments.

FierceBiotech · 3d

Metsera eyes $289M IPO to fund phase 3 weight loss trial

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its GLP-1 receptor agonist. | Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its GLP-1 receptor agonist.

BioSpace · 3d

Metsera Seeks $289M Raise, $1.78B Valuation in IPO

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

Reuters on MSN · 4h

Weight-loss drug developer Metsera raises $275 million in US IPO

(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company said on Thursday.

Hosted on MSN · 4h

Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care first-time share sales since October.

Seeking Alpha on MSN · 3d

Obesity drug developer Metsera sets terms for $275M IPO

Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. In a recent SEC filing, Metsera (MTSR) said it was looking to offer 17.

Reuters · 3d

Drug developer Maze Therapeutics eyes up to $728 million valuation in US IPO

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial public offering, set to be the first U.S.-based biotech firm to debut this year.

BioPharma Dive4h

Metsera, Maze secure combined $415 million in IPOs

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Metsera Readies $275 Million IPO For Obesity Treatments

Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...

Metsera Announces Pricing of Initial Public Offering

A registration statement on Form S-1 (File No. 333-284225) relating to the offering has been filed with the Securities and Exchange Commission and became effective on January 30, 2025. The offering is ...

15h

Metsera, Inc IPOs Tomorrow, Here's What You Need To Know

Metsera, Inc MTSR IPO will take place January, 31 on the NASDAQ exchange under the ticker MTSR. The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider ...